2 Information about eptinezumab

Marketing authorisation indication

2.1 Eptinezumab (VYEPTI, Lundbeck) is indicated for 'the prophylaxis of migraine in adults who have at least 4 migraine days per month'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for eptinezumab.


2.3 The price of eptinezumab is £1,350 for a 100 mg per ml vial (excluding VAT; BNF online accessed January 2023).

2.4 The company has a commercial arrangement. This makes eptinezumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.